CVRs

Bristol Myers dodges one $6.4B Celgene buyout CVR suit, but the battle is far from over
Fierce Pharma
Thu, 03/2/23 - 10:45 pm
Bristol Myers Squibb
Breyanzi
Celgene
legal
M&A
CVRs
BMS/Celgene merger payout evaporates as CVR deadline passes
Pharmaforum
Mon, 01/4/21 - 10:21 am
Celgene
Bristol-Myers Squibb
FDA
CVRs
An FDA inspection raises questions about Bristol Myers Squibb's liso-cel facility and the CVR, but analysts urge caution
Endpoints
Tue, 12/8/20 - 10:41 am
Bristol-Myers Squibb
liso-cel
drug manufacturing
Celgene
CVRs
Bristol Myers' $9 Celgene CVR is teetering on the brink of disaster as the FDA delays the liso-cel application yet again
Endpoints
Mon, 11/16/20 - 10:43 pm
Bristol-Myers Squibb
CVRs
Celgene
M&A
Could an FDA inspection scupper CVR deadline for BMS’ liso-cel?
Pharmaforum
Fri, 11/6/20 - 09:47 am
Bristol-Myers Squibb
liso-cel
CVRs
Can Sanofi push a CVR on Actelion after the Lemtrada fiasco?
Endpoints
Wed, 12/21/16 - 10:54 am
Sanofi
CVRs
Actelion
Lemtrada
M&A
Sanofi signals Lemtrada confidence with CVR buyback
Reuters
Tue, 09/4/12 - 05:25 pm
CVRs
Sanofi
Lemtrada
MS
multiple sclerosis
Sanofi/Genzyme CVRs plunge 40%
Marketwatch
Thu, 07/28/11 - 12:20 pm
Sanofi
Genzyme
CVRs
Sanofi / Genzyme Deal Throws Spotlight on CVRs
Seeking Alpha
Sun, 02/20/11 - 12:12 pm
Sanofi
Genzyme
CVRs
The Stats on Contingent Value Rights in Pharma Deals
WSJ Online
Mon, 02/14/11 - 12:09 pm
M&A
CVRs
Sanofi
Genzyme
Sanofi May Raise Genzyme Bid to $75, Plus CVR Payment, RBC Says
Bloomberg
Tue, 01/18/11 - 11:26 am
Sanofi
CVRs
Genzyme
M&A
CVRs could become a new trend in biotech M&A
Marketwatch
Tue, 01/11/11 - 12:33 pm
CVRs
biotech
M&A
Genzyme
Sanofi